World TB Day 2022

World TB Day Symposium 2022

Thursday 24th March 2022

Due to COVID, this was again an online event. 

The event is now on YouTube: Link to Sessions 1-3; Link to session 4 

World TB Day Symposium image and Eventbrite link


1230  Welcome and introductory remarks

Professor Marc Lipman (Director, UCL-TB director)
Professor Ibrahim Abubakar (Dean of the UCL Faculty of Population Sciences)
Professor Liam Smeeth (Director, LSHTM)

1245 Session 1 – Health consequences following tuberculosis

Microbiological cure of TB is not always the end of disease for many patients.  A significant proportion will suffer with complications of damage caused to the lungs and other organs post-TB.   This session will examine the challenges and consequences of post-TB sequelae across disciplines. Presentations and discussion will highlight the key health and economic consequences following TB and upcoming research priorities, including the re-prioritisation of screening interventions and potential therapy to prevent post-TB pathological damage. 

Chairs – Professor Katharina Kranzer (LSHTM) / Professor Marc Lipman (UCL)

Former TB Patient/Advocate: Patient experience of life after TB treatment – Recorded interview
Dr Matt Quaife (LSHTM) Health and economic costs of post-TB sequelae
Dr Gabriele Pollara (UCL) Rational strategies for host-directed therapy to minimize post-TB lung damage
Dr Toyin Togun (LSHTM) Post-TB lung health in children in West Africa

1345 Session 2 - Understanding Mycobacterium tuberculosis in the post- genomic era

Why is M. tuberculosis the world’s ‘most successful pathogen’? What parts of its known and unknown biology contribute to this reputation? In 1998, Stewart Cole et al. used Whole Genome Sequencing to paint a picture of an organism with unusual metabolism encoding 100’s of genes of unknown function. This has since been followed up with various Next Generation Sequencing applications revealing unique characteristics concerning evolution of drug resistance, resistance evasion and gene expression control. This session aims to showcase M. tuberculosis as an exceptional organism as well as a pathogen and how new techniques can bring fresh insight into disease treatments and control.

Chairs – Dr Isobella Honeyborne (UCL) / Dr Sam Willcocks (LSHTM)

Professor Tim McHugh (UCL) Post-genomic TB research and its role in diagnostics and drugs
Dr Gwen Knight (LSHTM) How mathematical models can be used to understand emergence of drug resistance in tuberculosis
Dr Dimitrios Evangelopoulos (UCL) What drives resistance evasion in TB: lessons from cycloserine
Dr Terry Kipkorir (UCL) Riboswitches, sensing and adapting to host environment via RNA through co- and post-transcriptional regulation

1450 - BREAK

    1520 Breaking news

    Chair – Professor Beate Kampmann (LSHTM)

    Dr Anna Turkova (UCL) SHINE trial and WHO paediatric TB guidance update

    1535 Session 3 - The impact of COVID-19 on TB

    The COVID-19 pandemic caused substantial disruption to health services and affected health seeking behaviour. TB notifications have reduced globally representing a significant setback for TB control. This session begins with a high-level overview of the impact of COVID-19 on TB prevention, diagnosis, care and treatment and solutions going forward. Following this, data on TB notifications before and after March 2020, from a range of settings, will be presented and interpreted followed by lessons learned going forwards. The modelled impact of COVID-19 on BCG vaccination uptake, and its implication for paediatric TB mortality, will be presented. And the implications of co-infection with COVID-19 for the accuracy of TB diagnosis will be explored using data from a 4-country cohort study.

    Chairs – Professor Beate Kampmann (LSHTM) / Professor Francois Balloux (UCL)

    Dr Rachael Burke (LSHTM / MLW) Effect of COVID on TB notification in Peru, South Africa and Malawi
    Ms Nabila Shaikh (LSHTM) Impact of COVID-19 on global BCG coverage and paediatric tuberculosis mortality
    Dr Jayne Sutherland (LSHTM/MRC Gambia) Influence of current and recent COVID on performance of novel TB diagnostics

      1620 – Handover to UCSF

      Dr Finn McQuaid (LSHTM) London closing remarks and switch to UCSF (link TBC)

      1630 Session 4 ­– Joint session on clinical trials with UCSF

      For our final session we will join forces with the University of San Francisco at the start of their World TB Day event for an exciting joint session on clinical trials. The session will address several aspects of trials, from implementation of novel design, evaluating stratified approaches, ensuring patient-centred approaches and maximum impact.

      Handover: Professor Marc Lipman (UCL)

      Chairs – Dr Gustavo Velasquez (UCSF) / Professor Angela Crook (UCL)

      Ms Annabelle South (UCL) What matters to DR-TB patients about their treatment? Results from a multi-national qualitative study
      Dr Bern-Thomas Nyang'wa (LSHTM / MSF) Clinical trial evidence to clinical practice - the PRACTECAL pathway
      Dr Patrick Phillips (UCSF) First time round the sun: Duration-randomisation TB clinical trial designs in the wild - DRAMATIC, UNITE4TB and SPECTRA-TB
      Dr Marjorie Imperial (UCSF) Lessons in stratified medicine from TBTC Study 31

      1730 Close of UCL/LSHTM Symposium

      The event is now on YouTube: Link to Sessions 1-3; Link to session 4

      The recording for the UCSF meeting is now available (­see UCSF programme)

      LSHTM TB Centre page for this event

      LSHTM-TB Centre and UCL-TB logos